4/2
07:30 am
inkt
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
Low
Report
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
4/1
08:01 am
inkt
MiNK Therapeutics (INKT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
MiNK Therapeutics (INKT) had its "buy" rating reaffirmed by HC Wainwright. They now have a $35.00 price target on the stock.
4/1
07:48 am
inkt
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [TheStreet.com]
Low
Report
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [TheStreet.com]
4/1
07:45 am
inkt
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [Yahoo! Finance]
Low
Report
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference [Yahoo! Finance]
4/1
07:30 am
inkt
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
Medium
Report
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
3/31
03:22 pm
inkt
MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
Low
Report
MiNK Therapeutics Inc (INKT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ... [Yahoo! Finance]
3/31
09:44 am
inkt
MiNK Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
MiNK Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/31
07:30 am
inkt
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
Low
Report
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
3/17
08:13 am
inkt
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs [Yahoo! Finance]
Medium
Report
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs [Yahoo! Finance]
3/17
07:30 am
inkt
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
Medium
Report
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
3/10
05:52 am
inkt
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers [Yahoo! Finance]
High
Report
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers [Yahoo! Finance]
3/10
05:30 am
inkt
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
High
Report
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
3/10
05:29 am
inkt
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology [Yahoo! Finance]
High
Report
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology [Yahoo! Finance]
3/10
05:00 am
inkt
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology
High
Report
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology
2/3
11:28 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]
2/3
09:30 pm
inkt
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Medium
Report
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
1/19
01:06 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Low
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
1/11
01:03 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was downgraded by analysts at
Wall Stree
1/8
12:00 pm
inkt
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
Low
Report
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
1/3
01:08 am
inkt
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street
Medium
Report
MiNK Therapeutics (NASDAQ:INKT) was upgraded by analysts at
Wall Street